Matrix Metalloproteinases and Descending Aortic Aneurysms: Parity, Disparity, and Switch
- 29 September 2011
- journal article
- review article
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 27 (1) , 81-90
Abstract
Central to the pathologic changes in developing aortic aneurysms are alterations in the abundance and activity of proteases, of which the most important for aneurysm production comprise the matrix metalloproteinase (MMP) family. In this review, literature demonstrating the role of MMPs in the development of aortic aneurysms is presented, with emphasis on the parity and disparity between the thoracic and abdominal aorta. Furthermore, the role of embryologic cellular origins and evidence of phenotypic switch will be addressed in terms of how this process alters MMP production during aneurysm development. (J Card Surg 2012;27:81–90)Keywords
This publication has 96 references indexed in Scilit:
- Cellular phenotype transformation occurs during thoracic aortic aneurysm developmentThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine modelAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Alterations in Aortic Cellular Constituents during Thoracic Aortic Aneurysm DevelopmentThe American Journal of Pathology, 2009
- Membrane-type 1 Matrix Metalloproteinase Regulates Macrophage-dependent Elastolytic Activity and Aneurysm Formation in VivoJournal of Biological Chemistry, 2009
- Regional heterogeneity within the aorta: Relevance to aneurysm diseaseThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Transforming Growth Factor-β Signaling in Thoracic Aortic Aneurysm Development: A Paradox in PathogenesisJournal of Vascular Research, 2008
- Altered Transforming Growth Factor-Beta Signaling in a Murine Model of Thoracic Aortic AneurysmJournal of Vascular Research, 2008
- Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled studyArthritis Research & Therapy, 2007
- Spatiotemporal expression and localization of matrix metalloproteinas-9 in a murine model of thoracic aortic aneurysmJournal of Vascular Surgery, 2006
- Differential Response of Mesoderm- and Neural Crest-Derived Smooth Muscle to TGF-β1: Regulation of c-myb and α1 (I) Procollagen GenesExperimental Cell Research, 1997